UNC Children’s Hospital suspends complex heart surgeries after media investigation

North Carolina Children’s Hospital has suspended heart surgeries for complex cases in the aftermath of an explosive New York Times investigation that found the hospital’s heart unit had an alarmingly high mortality rate.

The investigation found cardiologists, department leaders and the former head of the hospital were concerned about patients after heart surgery at the facility. Recorded audio even captured some doctors saying they wouldn’t trust the hospital to do surgeries on their own children. The mortality rate continued to rise after concerns were raised.

In response to the media investigation, the University of North Carolina-affiliated UNC Health Care, which operates the hospital, stated is would temporarily halt heart surgeries for the most complex cases and introduced a number of new initiatives to the heart surgery program, including an outside advisory board of medical experts and commitments to publicly release mortality data for the program.

The problems at the UNC hospital are reminiscent of high mortality rates in the pediatric heart unit of Johns Hopkins All Children’s Hospital in St. Petersburg, Florida, which was uncovered by The Tampa Bay Times last year. That revelation led to a CMS investigation and the resignations of several executives at the hospital.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.